Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that Ali Mortazavi, Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference on Tuesday, 13 March, 2018 at 10:30am EDT in Boston, MA.
The presentation will be webcast live and may be accessed by visiting Silence’s website at http://www.silence-therapeutics.com/investors/. A replay of the webcast will be available for 14 business days.
Silence Therapeutics plc develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
